Liraglutide Treatment to Patients With Severe Renal Insufficiency

Exclusion Criteria

• •Type 1 diabetes mellitus
• •Chronic pancreatitis / previous acute pancreatitis
• •Known or suspected hypersensitivity to trial product(s) or related products
• •Treatment with oral glucocorticoids, calcineurin inhibitors, dipeptidyl peptidase 4 (DPP4) inhibitors or other drugs, which in the Investigator's opinion could interfere with glucose or lipid metabolism 90 days prior to screening
• •Cancer (except basal cell skin cancer or squamous cell skin cancer) or any other clinically significant disorder which in the investigators' opinion could interfere with the results of the trial
• •Inflammatory bowel disease
• •Cardiac disease defined as: decompensated heart failure (NYHA class III-IV) and/or diagnosis of unstable angina pectoris and/or myocardial infarction within the last 6 months
• •Body mass index ≤ 18.5 kg/m2 or ≥ 50.0 kg/m2
• •Females of childbearing potential who are pregnant, breast-feeding, intend to become pregnant or are not using adequate contraceptive methods
• •Clinical signs of diabetic gastroparesis
• •Impaired liver function (transaminases \>two times upper reference levels)
• •Receipt of any investigational product 90 days prior to this trial
• •Known or suspected abuse of alcohol or narcotics
• •Screening calcitonin ≥50 ng/l
• •Subjects with personal or family history of medullary thyroid carcinoma or a personal history of multiple endocrine neoplasia type 2